Gore, gimps and a potty-mouthed magpie

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-09-11 • Permanent link

Fears of a measles outbreak have been heightened after the Centers for Disease Control and Prevention (CDC) questioned two measles deaths in Pennsylvania. The agency's decision has sparked concerns about the reliability of its data, particularly in light of recent cases of vaccine hesitancy. As a result, stocks in pharmaceutical companies such as Pfizer and Merck have taken a hit, with Pfizer's shares down 3% in pre-market trading. The CDC's handling of measles deaths has also raised questions about its ability to effectively track and respond to outbreaks.

What drove this controversy is a growing distrust of the CDC among some experts and lawmakers. A recent report by the CDC found that the number of measles cases in the US had declined by 90% since the introduction of the measles vaccine. However, some critics argue that the agency's reliance on data from voluntary reporting systems may lead to underestimation of actual cases. As a result, the CDC's decision to question the two Pennsylvania deaths has been seen as a step towards greater transparency and accountability.

The measles vaccine has been a cornerstone of public health efforts for decades, and its effectiveness is widely recognized. However, the rise of vaccine hesitancy and misinformation has created challenges for public health officials. In recent years, there has been a growing trend of anti-vaccination groups and social media influencers promoting misinformation about the safety and efficacy of vaccines. This has led to a decline in vaccination rates in some areas, and has raised concerns about the potential for outbreaks.

As the measles outbreak situation continues to unfold, investors and policymakers will be watching closely for any further developments. The CDC's decision to question the two Pennsylvania deaths is likely to lead to increased scrutiny of the agency's data collection and reporting practices. In the short term, this may lead to volatility in the pharmaceutical industry, as investors react to concerns about the safety and efficacy of vaccines. However, in the long term, it may also lead to greater investment in vaccine development and distribution, as policymakers recognize the importance of effective public health measures.